MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma

Oncogene

Volumn 27, Issue 43, 2008, Pages 5651-5661

  Fornari, F ^a   Gramantieri, L ^a,e   Ferracin, M ^b   Veronese, A ^b   Sabbioni, S ^b   Calin, G A ^c   Grazi, G L ^a   Giovannini, C ^a   Croce, C M ^b,d   Bolondi, L ^a   Negrini, M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cyclin dependent kinase inhibitors; HCC; microRNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; MESSENGER RNA; MIR 221 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; UPREGULATION;

3' UNTRANSLATED REGIONS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P57; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 52949127316     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.178     Document Type: Article

References (37)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. (2006). Phase II study of Sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
2. Bolondi L. (2003). Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 39: 1076-1084.
3. Bosch FX, Ribes J, Diaz M, Cleries R. (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
4. Bruix J, Sherman M. (2005). Practice guidelines committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
5. Calin GA, Croce CM. (2006). MicroRNA signatures in human cancer. Nat Rev Cancer 6: 857-866.
6. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu GC, Sabatino G et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358.
7. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949.
8. Diaz-Meyer N, Day CD, Khatod K, Maher ER, Cooper W, Reik W et al. (2003). Silencing of CDKN1C (p57/KIP2) is associated with hypomethylation at KvDMR1 in Beck with-Widemann syndrome. J Med Genet 40: 797-801.
9. Edmonson HA, Steiner PE. (1954). Primary carcinoma of the liver. A study of 100 cases among 48.900 necropsies. Cancer 7: 462-503.
10. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F et al. (2005). MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102: 18081-18086.
11. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA et al. (2007). MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting CDKN1B/p27. J Biol Chem 282: 23716-23724.
12. Gillies JK, Lorimer IA. (2007). Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6: 2005-2009.
13. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. (2007). Micro-RNA profilingin kidney and bladder cancers. Urol Oncol 25: 387-392.
14. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG et al. (2007). Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099.
15. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. (2005). The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080.
16. Hui AM, Sun L, Kanai Y, Sakamoto M, Hirohashi S. (1998). Reduced p27Kip1 expression in hepatocellular carcinomas. Cancer Lett 132: 67-73.
17. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N. (2001). Expression of CDKN1C/p57 protein in hepatocellular carcinoma. Oncology 61: 221-225.
18. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). Ras is regulated by let-7 microRNA family. Cell 120: 635-647.
19. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
20. Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A et al. (2007). Regulation of the CDKN1B/p27 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26: 3699-3708.
21. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL et al. (2006). Expression profilingidentifies microRNA signatures in pancreatic cancer. Int J Cancer 120: 1046-1054.
22. Lee MH, Yang HY. (2001). Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907-1922.
23. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. (2005). Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 11: 4587-9451.
24. Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. (2005). Imaging diagnosis. Semin Liver Dis 25: 162-170.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul JL, Zeuzem S et al. (2007). Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized placebo-controlled trial. ASCO Meeting, Chicago.
26. Nakai S, Masaki T, Shiratori Y, Ohgi T, Morishita A, Kurokohchi K et al. (2002). Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 20: 769-775.
27. Nan KJ, Guo H, Ruan ZP, Jing Z, Liu SX. (2005). Expression of CDKN1C/p57 and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol 11: 1237-1240.
28. Nan KJ, Jing Z, Gong L. (2004). Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma. World J Gastroenterol 10: 1425-1430.
29. Negrini M, Ferracin M, Sabbioni S, Croce CM. (2007). MicroRNAs in human cancer: from research to therapy. J Cell Sci 120: 1833-1840.
30. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
31. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R et al. (2004). Increased survival of cirrhotic patients with a hepatocellular carcinoma detected duringsurveillanc e. Gastroenterology 126: 1005-1014.
32. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L et al. (2000). Gain of imprintingat chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 97: 5445-5449.
33. Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S et al. (2004). Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene 23: 4380-4388.
34. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Köckerling F, Haugwitz U et al. (2000). Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 89: 350-355.
35. Visone R, Russo L, Pallante P, De Martino I, Ferrero A, Leone V et al. (2007). MicroRNAs miR-221 and miR-222, both over-expressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14: 791-798.
36. Yan Y, Frisén J, Lee MH, Massagué J, Barbacid M. (1997). Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation duringmouse development. Genes Dev 11: 973-983.
37. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC et al. (1997). Altered cell differentiation and proliferation in mice lackingp57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387: 151-158.